An interventional study of Edoxaban 60 mg and Enoxaparin 40 mg in Nephrotic Syndrome and Hypoalbuminemia, sponsored by Peking University People's Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to evaluate the impact of nephrotic syndrome on the steady state pharmacokinetics and pharmacodynamics of edoxaban compared to health volunteers, and whether edoxaban can provide an equivalent anticoagulant effect to enoxaparin sodium.
192 studies on the registry are indexed under Nephrotic Syndrome; 65 are open to participants now.
This study's planned enrollment of 60 is above the median of 46 across 122 interventional studies indexed under Nephrotic Syndrome.
Browse Nephrotic Syndrome studies →Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Nephrotic syndrome Group:
Healthy volunteer Group:
Exclusion Criteria:
Use of (but not limited to) the prescription medications that are inhibitors or inducers of and/or P-gp within the past 14 days:
CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, etc.) ②CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, etc.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with mild hypoalbuminemia (serum albumin \>25g/L and \<30g/L), taking edoxaban 60mg orally once daily
Drug: Edoxaban 60 mg
Patients with severe hypoalbuminemia (serum albumin ≤25g/L), taking edoxaban 60mg orally once daily
Drug: Edoxaban 60 mg
Patients with mild hypoalbuminemia (serum albumin \>25g/L and \<30g/L), injecting enoxaparin sodium 0.4ml subcutaneously once daily
Drug: Enoxaparin 40 mg
Patients with severe hypoalbuminemia (serum albumin ≤25g/L), injecting enoxaparin sodium 0.4ml subcutaneously once daily
Drug: Enoxaparin 40 mg
Healthy volunteers, taking edoxaban 60mg orally once daily
Drug: Edoxaban 60 mg
film-coated tablet, manufactured by Daiichi Sankyo Europe GmbH
Also known as: LIXIANAN
enoxaparin sodium, prefilled syringe of 0.4mL injectable solution, manufactured by SANOFI WINTHROP INDUSTRIE
Also known as: CLEXANE
area under the steady-state plasma concentration-time curve (AUCss)
① Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: area under the steady-state plasma concentration-time curve (AUCss)
Time frame: Day 4 post-administation
time to peak (Tmax)
Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: time to peak (Tmax)
Time frame: Day 4 post-administation
trough concentration at steady state (Css_min)
Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: trough concentration at steady state (Css\_min)
Time frame: Day 4 post-administation
peak concentration at steady state (Css_max)
Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: peak concentration at steady state (Css\_max)
Time frame: Day 4 post-administation
elimination half-life (t1/2)
Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: elimination half-life (t1/2)
Time frame: Day 4 post-administation
average steady-state plasma concentration (Css_av)
Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: average steady-state plasma concentration (Css\_av)
Time frame: Day 4 post-administation]
apparent volume of distribution (Vd/F)
Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: apparent volume of distribution (Vd/F)
Time frame: Day 4 post-administation
clearance (CL/F)
Steady-state PK parameters of edoxaban in nephrotic syndrome patients versus healthy volunteers: clearance (CL/F)
Time frame: Day 4 post-administation
anti-FXa activity
Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: anti-FXa activity
Time frame: Day 4 post-administation
prothrombin time (PT)
Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: prothrombin time (PT)
Time frame: Day 4 post-administation
activated partial thromboplastin time(APTT)
Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: activated partial thromboplastin time(APTT)
Time frame: Day 4 post-administation
antithrombin Ⅲ(AT-III)
Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: antithrombin Ⅲ(AT-III)
Time frame: Day 4 post-administation
Protein C
Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: Protein C
Time frame: Day 4 post-administation
Protein S
Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: Protein S
Time frame: Day 4 post-administation
D-Dimer
Steady-state PD parameters of edoxaban versus enoxaparin in nephrotic syndrome patients: D-Dimer
Time frame: Day 4 post-administation
Safety Assessment
Adverse events will be collected and coded according to the Medical Dictionary for Regulatory Activities (MedDRA)
Time frame: from the date of informed consent form signature to day 8 post-administration
No study locations are listed for this record.
Start is estimated for Sep 2025; primary completion for Feb 2026, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edoxaban
Peking University People's Hospital →